Application of Didroprogesterone Tablets as Adjuvant Chemotherapy in the Improvement of Tumor Markers and Inflammatory Reaction of Endometrial Carcinoma
Objective:To observe the effect of didroxyprogesterone tablets on serum tumor markers and inflammatory reaction in patients with endometrial cancer.Methods:Through taking 80 patients with endometrial cancer treated in the hospital from January 2018 to October 2021 as the research object,they were divided into two groups by drawing lots,and listed 40 patients who received chemotherapy alone as the control group,and 40 patients who received adjuvant chemotherapy with didroxyprogesterone tablets as the observation group.The serum tumor marker levels,inflammatory indicators and focal remission rates of the two groups before and after treatment were compared,and all patients were followed-up for one year.The quality of life and the occurrence of adverse events of the two groups were compared.Results:After treatment,CEA,CA19-9,and HE4 in the observation group were lower than those in the control group(t=2.520,2.786,2.140;P＜0.05).WBC,NE,and CRP levels were lower than those in the control group(t=3.147,2.523,2.667;P＜0.05).The focal remission rate was higher than the control group(x2=5.643,P＜0.05).During the follow-up period,the QLICP-EN scores of the observation group were higher than those of the control group(t=2.216,2.827,2.629,2.394;P＜0.05).The incidence of adverse events were lower than the control group(x2=5.741,P＜0.05).Conclusion:The use of didrogesterone tablets in adjuvant chemotherapy for endometrial cancer can effectively control the level of tumor markers and alleviate inflammatory reaction,which is of positive significance in promoting the improvement of its lesions,improving the quality of life and reducing the risk of adverse events.
万方数据
维普
